Compare Citius Pharmaceuticals Inc (CTXR) vs MINISO Group Holding Ltd (MNSO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs MINISO Group Holding Ltd — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while MINISO Group Holding Ltd trades at $12.37 (market cap $3.46B). The key difference: MINISO Group Holding Ltd is far larger — about 236.3× Citius Pharmaceuticals Inc's market cap, and MINISO Group Holding Ltd pays a 5.78% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | MNSO | |
|---|---|---|
Market Cap | $14.64M | $3.46B |
Sector | Health | Technology |
52-Week High | $1.82 | $26.63 |
52-Week Low | $0.53 | $11.30 |
Enterprise Value | $10.86M | $4.13B |
Dividend Yield | — | 5.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
MNSO trades at $11.42, down 3.14% on the day, reflecting recent volatility. The stock shows mixed signals with a bearish technical trend but solid fundamentals, including a P/E of 11.73 and net income margin of 8.98%. Recent corporate actions include a $0.38 dividend and a HK$2 billion share repurchase program announced on June 29, 2026, signaling management confidence. Q1 2026 earnings beat expectations with EPS of $0.591 versus $0.238 expected, though prior quarters missed estimates.
Outlook is cautiously optimistic given strong profitability metrics and shareholder-friendly actions, but risks include margin pressures from overseas expansion and technical bearishness. With 75% analyst buy ratings and an undervalued GF Score per GuruFocus on June 29, 2026, the stock offers value if execution improves, though investors should monitor earnings consistency and global economic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →
